Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Journal Articles

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Wendy E. Owens, MA, Anisha M. Patel, PhD, Kathleen Poulos, RN, Janet Bernard, BA, Janet Powers, MPH, MBA, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 4941.

https://doi.org/10.1182/blood-2019-123730

Published: 2019

Journal Articles

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

Bruce A. Sullenger, PhD

Blood (2019) 134 (Supplement_1): SCI-16.

https://doi.org/10.1182/blood-2019-121056

Published: 2019

Journal Articles

Cofactor and Cofactor Mimetics

Peter J. Lenting, PhD

Blood (2019) 134 (Supplement_1): SCI-17.

https://doi.org/10.1182/blood-2019-121059

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Antithrombin- and Heparin-Binding Exosites Regulate Extravascular Binding and Clearance of Factor IXa

Pamela Westmark, PhD, John P. Sheehan, MD

Blood (2019) 134 (Supplement_1): 2392.

https://doi.org/10.1182/blood-2019-131580

Published: 2019

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

A Novel Variant of Factor VIII Yields Cofactor Activity without Proteolysis between the A1 and A2 Domains

Manjunath Goolyam Basavaraj, PhD, Sriram Krishnaswamy, PhD

Blood (2018) 132 (Supplement 1): 3771.

https://doi.org/10.1182/blood-2018-99-116267

Published: 2018

Journal Articles

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Michael A Suster, PhD, Debnath Maji, M.Tech, Lalitha V. Nayak, MD, Christina Jenkins, MSN-PNP, RN, Susan Hunter, BSN, RN-BC, Alvin H. Schmaier, MD, Pedram Mohseni, PhD, Sanjay Ahuja

Blood (2018) 132 (Supplement 1): 2475.

https://doi.org/10.1182/blood-2018-99-113623

Published: 2018

Journal Articles

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

Dougald Monroe, PhD, Maureane Hoffman, MD

Blood (2018) 132 (Supplement 1): 1167.

https://doi.org/10.1182/blood-2018-99-116888

Published: 2018

Journal Articles

Inhibition of Factor IXa By Protein S: Critical Function of the Protein S SHBG-like Domain

Rima Chattopadhyay, PhD, A'drianne Dorsey, Satish Pilli, PhD, Sumita Choudhury, PhD, Rinku Majumder, PhD

Blood (2017) 130 (Supplement 1): 2343.

https://doi.org/10.1182/blood.V130.Suppl_1.2343.2343

Published: 2017

Journal Articles

Activated Factor IX As a Candidate for the Initial Protease in the Coagulation Cascade

Tina M Misenheimer, PhD, Kraig T Kumfer, MD PhD, Barbara E Bates, MS, Brad S Schwartz, MD

Blood (2017) 130 (Supplement 1): 235.

https://doi.org/10.1182/blood.V130.Suppl_1.235.235

Published: 2017

Journal Articles

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Yesim Dargaud, MD PhD, Anne Lienhart, MD, Nathalie Enjolras, PhD, Claude Negrier, MD

Blood (2017) 130 (Supplement 1): 3675.

https://doi.org/10.1182/blood.V130.Suppl_1.3675.3675

Published: 2017

Journal Articles

Regulation of Factor VIII By Activated Protein C: Assessment In Vitro and In Vivo

Nicole A. Parsons, B.S., Michelle D. Ho, BS, Robert J. Davidson, BS, Nabil K. Thalji, PhDMD, Ben J. Samelson-Jones, MD PhD, Rodney M Camire, PhD, Lindsey A. George, MD

Blood (2017) 130 (Supplement 1): 3650.

https://doi.org/10.1182/blood.V130.Suppl_1.3650.3650

Published: 2017

Journal Articles

Targeting Factor Xa Expression in Platelets As a Potential Gene Therapy Strategy for Hemophilia with Inhibitors

Dawei Wang, Xiaohu Shao, Guowei Zhang, PhD, Shuxian Yao, Xielai Zhou, Jianhua Mao, PhD, Zhugang Wang, Zhu Chen, Saijuan Chen

Blood (2016) 128 (22): 1171.

https://doi.org/10.1182/blood.V128.22.1171.1171

Published: 2016

Journal Articles

Identification of the Protein S Binding Site in the Factor IXa Serine Protease Domain Presents Therapeutic Possibilities

William E. Plautz, Satish Sekhar, Rinku Majumder, PhD, John P. Sheehan, MD

Blood (2015) 126 (23): 2274.

https://doi.org/10.1182/blood.V126.23.2274.2274

Published: 2015

Journal Articles

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

Muhammad Kashif Riaz, MD, Saulius Girnius, MD, Joseph Edward Palascak, MD FACP

Blood (2015) 126 (23): 4676.

https://doi.org/10.1182/blood.V126.23.4676.4676

Published: 2015

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

Cofactor and Cofactor Mimetics

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Antithrombin- and Heparin-Binding Exosites Regulate Extravascular Binding and Clearance of Factor IXa

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

A Novel Variant of Factor VIII Yields Cofactor Activity without Proteolysis between the A1 and A2 Domains

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

Inhibition of Factor IXa By Protein S: Critical Function of the Protein S SHBG-like Domain

Activated Factor IX As a Candidate for the Initial Protease in the Coagulation Cascade

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Regulation of Factor VIII By Activated Protein C: Assessment In Vitro and In Vivo

Targeting Factor Xa Expression in Platelets As a Potential Gene Therapy Strategy for Hemophilia with Inhibitors

Identification of the Protein S Binding Site in the Factor IXa Serine Protease Domain Presents Therapeutic Possibilities

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only